India’s minimally invasive glaucoma surgery (MIGS) devices market is witnessing a steady growth, driven by the rising prevalence of glaucoma and increasing adoption of advanced ophthalmic technologies to improve clinical outcomes. Against this backdrop, the MIGS devices market in India is anticipated to grow at a compound annual growth rate (CAGR) of approximately 2% through 2033, according to GlobalData, a leading intelligence and productivity platform.

GlobalData’s report, “India Glaucoma Surgery Devices Market Outlook to 2033 – Glaucoma Drainage Devices and Minimally Invasive Glaucoma Surgery (MIGS) Devices,” reveals that India accounted for nearly 22% of the Asia-Pacific (APAC) MIGS market in 2026.

Prerna Gupta, Medical Devices Analyst at GlobalData, comments: “The increasing adoption of MIGS devices in India is driven by the rising burden of glaucoma, greater awareness and training among ophthalmologists, and growing patient demand for safer interventions with fewer complications and faster recovery. The adoption is further supported by the expanding ophthalmic infrastructure and the increasing use of MIGS with cataract surgery.”

Within this evolving market landscape, eye care device company Alcon has launched Hydrus Microstent in March 2026. The device is designed to lower intraocular pressure in patients with mild to moderate open-angle glaucoma when implanted during cataract surgery, providing a minimally invasive approach to long-term disease management.

The Hydrus Microstent works by dilating and supporting the scleral venous sinus to improve aqueous humor outflow, thereby helping to reduce intraocular pressure. Clinical data from the HORIZON randomized multi-center trial have demonstrated sustained pressure reduction and reduced need for glaucoma medications when the device is used alongside cataract surgery, supporting its role as an effective minimally invasive glaucoma treatment option.

Gupta concludes: “Even though cost and limited access outside urban areas are still obstacles, new products such as Alcon’s Hydrus Microstent, supported by long-term clinical evidence, can build physician confidence and gradually increase the use of MIGS as a safe, effective addition to cataract surgery for glaucoma treatment in the coming years.”